(Reuters) – Consumer healthcare group Haleon expects 2023 organic revenue growth towards the upper end of its 4%-6% forecast, it said on Thursday, on strong demand and the restocking of its respiratory health products due to a bad cold and flu season.
The company, the world’s biggest standalone consumer health business that sells non-prescription drugs, vitamins and oral care products, kept the rest of its full-year 2023 outlook unchanged.
Haleon was carved out of British drugmaker GSK in July last year.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Janane Venkatraman)
